Hedgehog (Hh) proteins are one of a small number of families of secreted signalling proteins that are responsible for cell interactions during development in many animals. As such, Hh signals produce many different responses at different times and in different cells. As for other multifunctional ligands, this requires regulated patterns of expression, special mechanisms for ligand movement between cells and ligand destruction, and mechanisms for integrating a generic signalling state (on or off) with the status of responding cells in order to produce an appropriate cell-specific response. Here I discuss what is known about the biochemical mechanisms by which an Hh signal is transduced in order to change the patterns of gene transcription.
Experimental approaches
It is vitally important to understand how the secreted family of Hh (hedgehog) signalling proteins alter cell behaviours because of the widespread developmental functions of Hh signalling in metazoa and the clinical manifestations of insufficient Hh signalling (holoprosencephaly) or excessive Hh signalling pathway activity (multiple forms of cancer) in humans [1] [2] [3] . At present, we have an incomplete understanding of the mechanism of Hh signal transduction [4, 5] . Although plausible schemes can be drawn and described, they invariably include causative links that are simply the most economical or conventional explanations of existing data rather than being rigorously proven. Hence, it is not yet clear whether only details or major issues are missing from these models. Before examining these specific models, it is therefore worth considering what has limited our insights into Hh signalling. This should help the reader to assess which aspects of models are secure and to see how more definitive insights might be obtained in the future.
Initial insights into Hh signalling came from molecular genetic studies in Drosophila, and this remains the most definitive testing ground of normal protein functions [1] . Thus functional studies of moderate complexity can be organized using genetics of Drosophila and other organisms, together with some tissue culture cell models, but these are currently limited in the ability to study stepwise consequences of perturbations in detail and to follow signalling dynamically. In vitro biochemical studies are starting to become more comprehensive, for example, mapping precise interaction domains or sites of phosphorylation, but are still rarely quantitative and have not reached the stage of building up physiologically relevant cascades of interaction in vitro from purified components. Furthermore, the relevance of detailed biochemical studies in artificial situations where proteins are Key words: CK1, Cubitus interruptus (Ci), glycogen synthase kinase 3 (GSK3), hedgehog, phosphorylation, protein kinase A. Abbreviations used: Cos2, costal-2; Ci, Cubitus interruptus; Fu, fused; GSK3, glycogen synthase kinase 3; GRK, G-protein-coupled-receptor kinase; Hh, hedgehog; LMB, leptomycin B; Ptc, patched; PKA, protein kinase A; Smo, smoothened; Su(fu), suppressor of Fu. 1 email ddk1@columbia.edu overexpressed is open to question for the Hh signal transduction system in which subcellular localization and relative stoichiometries of several components are known to be important.
A quintessential illustration of the strength and weakness of current experimental approaches is the biochemistry of Ci (Cubitus interruptus), the transcriptional effector of the Hh signalling pathway in Drosophila. It has been demonstrated by rigorous genetic techniques in the best studied developmental paradigms that Ci is essential for any response to Hh, that synthetic activation of Ci can phenocopy an Hh response and that the properties of Ci are extensively altered in response to Hh [6, 7] . Thus understanding how Ci is altered during Hh signalling is key to understanding signalling. However, only a tiny proportion of Ci is seen in the nucleus of cells responding to Hh [8] . Hence, it is not straightforward to isolate the active form of Ci from cells in order to characterize it biochemically, let alone to discern how this activated form was produced. Biochemical studies on bulk Ci from cells would be valuable if active nuclear Ci is essentially equivalent to, and in equilibrium with, bulk Ci in the cytoplasm, but this is not certain. Active Ci might be very different, with different binding partners and different post-translational modifications, or it might even be altered in its primary amino acid sequence, for example, by proteolytic events. With these limitations in mind, I discuss below some plausible biochemical models of Hh signal transduction in Drosophila.
The first steps: transduction by the integral membrane proteins Ptc (patched) and Smo (smoothened)
The basic outline of Hh signalling includes the major components that constitute a receptor, a transduction complex, a transcriptional effector and some observed changes in these components in the presence and absence of Hh. Ptc is the Hh receptor. It binds Hh directly and loss of Ptc activity can turn the pathway on fully whether Hh is present or not [1] . Coreceptors have not been identified but cannot be excluded by genetic or biochemical experiments performed to date. Smo is a seven-transmembrane domain protein that is a key link between Ptc and the rest of the transduction complex. Smo associates physically with other transduction complex components through binding to Cos2 (costal-2) and Smo activity is essential for any response either to Hh or to genetic loss of Ptc activity [9] [10] [11] [12] [13] . Thus Smo appears clearly to act downstream of Ptc.
Ptc was originally found to contact Smo directly but these observations are generally now considered as artifacts of assays employing overexpressed proteins because they are not easily reproduced under different conditions, because Ptc and Smo exhibit minimal precise co-localization in cells and because one molecule of Ptc appears to be capable of silencing many molecules of Smo [14] [15] [16] [17] [18] . Ptc and Smo are the only known integral membrane proteins in the pathway and mutations of other pathway components that constitutively activate the pathway are invariably epistatic to Smo loss-offunction mutations. It is therefore simplest to suggest that Ptc (which itself is altered by binding to Hh) affects the pathway solely by altering Smo in some manner. However, it is also possible that Ptc might modify other pathway components without acting through Smo. This possibility is hard to exclude because (a proportion of) Smo is physically complexed to other transduction proteins in the presence and absence of Hh and because there is no direct assay of Smo activity or of an active conformation of Smo [10] . Thus Smo activity cannot be measured in isolation; instead, Smo activity is always inferred from an assay that is dependent on additional transduction components. Generally, this assay is simply transcriptional output from the entire pathway.
Following the simplistic view that Ptc acts solely by altering properties of Smo, we can search for such a mechanism. In the absence of Hh, Ptc does limit Smo protein levels posttranscriptionally and it limits the proportion of Smo at the plasma membrane [14, 19] . Guided by sequence similarities, these accomplishments of Ptc are hypothesized to derive from altered trafficking of Smo-containing vesicles or from Ptc-mediated transport of low molecular mass agonists or antagonists across Smo-containing vesicles [18] . Vertebrate Smo binds several such synthetic agonists and antagonists related in structure to the naturally occurring antagonist cyclopamine, although this sensitivity is not conserved in Drosophila Smo [20, 21] . In Drosophila, exposure of cells to Hh increases total Smo protein levels and the proportion of Smo at the cell surface, but an analogous effect has not been clearly documented for vertebrate Smo in a physiological setting [14, 19] . Nevertheless, there is evidence from both Drosophila and mammalian tissue culture cell studies that changes in the distribution of Smo may be accomplished by diverting endosomal Smo from a lysosomal fate to the plasma membrane [16, 22] . The molecular mechanism for regulated trafficking of Smo has not been defined and, despite several supportive correlations [11, 16, 23, 24] , there is no definitive proof that Smo localization or Smo levels are the key (necessary or sufficient) changes that lead to a transcriptional response. They may instead be secondary responses or just one aspect of the critical activating changes in Smo biology induced by Hh. Indeed, essential changes in Smo can be evaluated only once we understand how these affect downstream components in the pathway.
Cytoplasmic transduction complexes: Ci proteolysis, cytoplasmic tethering and more
Many of the transduction components considered downstream of Smo (in the simplified view of Smo relaying all regulation from Ptc) are binding partners of both Smo and the transcriptional effector of the pathway, Ci. A central component is Cos2, which at the least acts as a passive, complex scaffold [25, 26] . More likely, Cos2 is also instrumental in actively transmitting the Hh signal [11] . Cos2 can bind to at least two regions of Ci and it can also bind three kinases known to act directly on Ci [PKA (protein kinase A), GSK3 (glycogen synthase kinase 3) and CK1 (protein kinase CK1)] and another kinase, Fu (fused), which regulates the activity of Ci [27] [28] [29] [30] . Another component that can bind both Ci (in two regions) and Fu is Su(fu) (suppressor of Fu) [27, 29] . Although tetrameric complexes containing Cos2, Ci, Fu and Su(fu) can be assembled in vitro, the majority of cellderived Ci complexes (that are stable under the conditions of extraction and analysis used) contain either Cos2 or Su(fu) but not both [11, 31] . Fu is invariably associated with Cos2 and the stabilities of these two molecules appear to be interdependent [13] . The roles of these different complexes in controlling different aspects of Ci biology are discussed below.
The key known aspects of Ci biology concern changes in response to Hh. In the absence of Hh, full-length Ci (Ci-155) is slowly converted into a truncated form (Ci-75), which retains the DNA-binding domain, localizes efficiently to the nucleus and is an active transcriptional repressor of Hh target genes [6, 7, 32, 33] . The considerable steady-state levels of Ci-155 are held largely in the cytoplasm, even after treatment with a drug, LMB (leptomycin B), that inhibits nuclear export of Ci-155, and Ci-155 does not activate transcription in the absence of Hh [8, 34] . In the presence of Hh, Ci-155 is no longer converted into Ci-75, Ci-155 levels increase (perhaps 3-5-fold at most) and transcription of Hh target genes is activated. Ci-155 readily accumulates in the nucleus in the presence of both LMB and Hh but is still almost exclusively cytoplasmic in the absence of LMB. Thus Hh blocks Ci-155 proteolysis, increases Ci-155 levels and increases the specific activity of Ci-155, at least in part by facilitating its nuclear entry or retention.
Loss of Cos2 prevents conversion of Ci-155 into Ci-75, allows nuclear accumulation of Ci-155 in the presence of LMB and causes some (but not maximal) ligand-independent activation of Hh target genes [26, 34] . In contrast, loss of Su(fu) does not prevent formation of Ci-75 and does not by itself induce ectopic Hh target gene expression [35, 36] . Loss of Su(fu) does, however, accentuate the transcriptional response to loss of Cos2. Thus Cos2 complexes are thought to facilitate conversion of Ci-155 into Ci-75 and to sequester Ci-155 in the cytoplasm, whereas a major function of Su(fu) complexes is thought to be limitation of Ci-155 activity once it has escaped Cos2 inhibition (either through the genetic inactivation of Cos2 or during normal Hh signalling). Su(fu) appears to have some role in limiting Ci-155 accumulation in the nucleus but it also may accompany Ci (or their vertebrate homologues, the GLI proteins) into the nucleus where Su(fu) may recruit co-repressor complexes [28, 37, 38] . Loss of Fu kinase activity does not affect production of Ci-75 but reduces the transcriptional response to Hh [35] . This reduced response to Hh is suppressed by loss of Su(fu) [35, 36, 39, 40] . Hence, Fu kinase activity is thought to mediate the release of Ci from Su(fu) inhibition.
In biochemical terms, the above ideas could be incorporated as follows. Newly synthesized Ci is efficiently trapped by Cos2. In the absence of Hh, this sequesters Ci-155 in the cytoplasm and promotes conversion into Ci-75 such that (i) Ci-75 represses target genes and (ii) Ci-155 levels never exceed the capacity of Cos2 to restrain its activity. In the presence of Hh, there are changes that prevent conversion of Ci-155 into Ci-75 (discussed below) and (more speculatively) which allow Su(fu) to enter the Cos2-Fu-Ci complex. The hypothesized entry of Su(fu) prevents release of free Ci-155 from Cos2. Fu can then act on its critical substrate [perhaps Su(fu) or Cos2] and this permits dissociation of some Ci-155 from Cos2 in a form that is able to enter the nucleus and activate transcription. In the genetic absence of Su(fu), Hh signalling allows dissociation of active Ci-155 from Cos2 without the need for participation of Fu kinase activity.
Regulation of Ci-155 proteolysis by phosphorylation
The conversion of Ci-155 into Ci-75 requires the activity of three protein kinases and the activity of 'SCF' (SkpCullin-F-box) complexes that include Slimb [homologue of vertebrate β-TrCP1 (β-transducin repeat-containing protein 1)] as the F-box component primarily responsible for recognizing suitable substrates for ubiquitination [41] [42] [43] . Specific serine residues in Ci-155 have been identified as being both required for conversion into Ci-75 and subject to phosphorylation by PKA, CK1 and GSK3 [41, 43] . Furthermore, these protein kinase activities are also required for Ci-155 proteolysis [41, 43, 44] . It is likely, but not yet proven, that these phosphorylated sites are directly recognized by Slimb. The precise epitopes that Slimb binds have not been defined but it is likely that several such epitopes are created by extensive phosphorylation of an 80 amino acid stretch of Ci that includes the PKA, CK1 and GSK3 sites. The phosphorylation status of this region of Ci-155 has not yet been measured directly in any detail but there is some evidence that Hh prevents Ci-155 proteolysis (and perhaps also inactivation) by reducing the degree of Ci-155 phosphorylation [8, 30, 34] . An additional complication is that Ci-155 also appears to be proteolysed (to completion) in lysosomes in a manner that is also dependent on phosphorylation and Slimb activity [45] . It is not clear what determines whether phosphorylated Ci is partially or completely proteolysed, or whether Hh signalling prevents both forms of proteolysis by the same mechanism.
If Hh indeed regulates Ci-155 proteolysis and perhaps also its specific activity by regulating Ci-155 phosphorylation, how is this achieved? A crucial intermediary may be Cos2. Cos2 is required for efficient Ci-155 phosphorylation [30] . Furthermore, in response to Hh, Cos2 becomes hyperphosphorylated and its avidity for PKA, CK1 and GSK3 is reduced [30] . Whether these two changes in Cos2 are causally linked has not been investigated, nor have functionally relevant sites of phosphorylation on Cos2 been defined. It also remains to be shown whether regulated association of PKA, CK1 and GSK3 with Cos2, or regulated phosphorylation of specific sites on Ci, are essential to Hh signalling.
The role of Smo phosphorylation by PKA and CK1
Now that some potentially critical features of other transduction components have been outlined we can return to the question of how Smo influences Ci biology: whether it is through Cos2 or otherwise? Smo binds to Cos2 both in the presence and absence of Hh, without any obvious Hhdependent change in affinity [9, [11] [12] [13] . This interaction therefore linearly transduces the increased Smo levels and increased proportion of Smo at the plasma membrane observed during Hh signalling into increases in the proportion of Cos2 (and the rest of the Ci complex) that is associated with Smo and the proportion that is at the plasma membrane. Are these changes crucial or are there other key changes in conformation, binding partners or affinities of Cos2 that are transmitted by Hh-dependent changes in the conformation or state of modification of Smo?
The status of Smo phosphorylation is one important aspect to consider. Smo becomes hyperphosphorylated during Hh signalling [14] . Among the phosphorylated residues in Smo are several PKA and PKA-primed CK1 sites in its long C-terminal tail, arranged in a manner very similar to that in Ci [46] . Loss of these PKA or CK1 sites renders Smo inactive, whereas alteration of multiple serine residues to acidic residues produces signalling activity even in the absence of Hh [23, 46, 47] . Although it is therefore tempting to conclude that the degree of phosphorylation of these sites is increased by Hh, this has not yet been measured directly. Furthermore, Smo with acidic residues in place of PKA and CK1 site serine residues can be activated further by Hh, indicating additional Hh-induced changes in Smo (conceivably involving additional phosphorylation sites).
At the least, some degree of phosphorylation of Smo, whether constitutive or Hh-dependent, is required for pathway activation. Why is this? Plausibly, these phosphorylations may regulate trafficking of Smo, or the exact way in which Smo interacts with Cos2, or perhaps this phosphorylated region might compete with the analogous region of Ci for a binding partner. The most logical such binding partner would be Cos2 because this would allow release of Ci (and cut short any hypothetical positive feedback loop between increased Ci phosphorylation and increased binding to Cos2). However, the known mapped Cos2 interaction domains for both Ci and Smo (determined using unphosphorylated proteins) lie outside the sites of PKA and CK1 phosphorylation, so there is currently no substantive support for the model of phosphorylated Smo and Ci competing for a Cos2 interaction [9, 11] . During Hh signalling, the association of PKA, CK1 and GSK3 with Cos2 was observed to decrease [30] . This suggests that the conformation of Cos2 might change considerably or that Cos2 acquires binding partners that compete with these kinases during Hh signalling. Perhaps such a protein is brought into the complex by an Hh-induced association with Smo (directly sensing a specific Smo conformation or state of phosphorylation). Finally, the idea that phosphorylation might affect trafficking of Smo is particularly intriguing in the light of recent investigations in vertebrate Hh signalling, which indicate a positive signalling role for the association of Smo with arrestin following phosphorylation at GRK2 (G-protein-coupledreceptor kinase 2) sites [48, 49] . Arrestins are well known for directing traffic of phosphorylated receptors [50] . It is not clear if Drosophila Smo also has GRK sites but it is possible that the Drosophila Smo PKA and CK1 sites serve an equivalent purpose since such sites are absent from vertebrate Smo proteins.
Although many of these suggested models are plausible and have some precedents, we must return to a central problem emphasized at the outset. It is extremely difficult to relate the various observed changes in Smo, Cos2 and Ci biology temporally by direct observation and causally. This is an especially challenging task because many of the changes (in phosphorylation, for example) are complex and because we cannot easily determine what magnitude of change is functionally significant. Nevertheless, detailed biochemistry and rigorous functional tests will no doubt continue to clarify how this crucial signal transduction pathway fulfils its functions biochemically, and perhaps in the more distant future we will be able to observe the movements and modification of single Ci molecules from synthesis to Hh target gene activation.
